Form Type: 4

SEC EDGAR Link
Accession Number:0000899866-21-000068
Date:2021-07-21
Issuer: ALEXION PHARMACEUTICALS, INC. (ALXN)
Original Submission Date:

Reporting Person:

CHINIARA ELLEN
C/O ALEXION PHARMACEUTICALS, INC.
121 SEAPORT BOULEVARD BOSTON, MA 02210

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK, PAR VALUE $.0001 PER SHARE 2021-07-21 D 116,850 d $0.00 0 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 represents shares of alexion common stock disposed in connection with the agreement and plan of merger (the "merger agreement") dated as of december 12, 2020, by and among alexion and astrazeneca plc. in accordance with the merger agreement, upon the first effective time (as defined in the merger agreement), each share of alexion common stock was converted into the right to receive (i) 2.1423 american depositary shares (adss) of astrazeneca plc and (ii) $60.00 in cash (the "merger consideration").
WhaleWisdom Logo

Elevate your investments